Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity

Journal of Urology

Volumn 187, Issue 6, 2012, Pages 2131-2139

  Ginsberg, David ^a   Gousse, Angelo ^d   Keppenne, Veronique ^e   Sievert, Karl Dietrich ^f   Thompson, Catherine ^b   Lam, Wayne ^b   Brin, Mitchell F ^c   Jenkins, Brenda ^b   Haag Molkenteller, Cornelia ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b ALLERGAN INC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^e UNIVERSITY OF LIÈGE   (Belgium)

^f UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

botulinum toxin; multiple sclerosis; onabotulinumtoxinA; spinal cord injuries; urinary incontinence

Indexed keywords

BOTULINUM TOXIN A; PLACEBO;

ADULT; AGED; ARTICLE; AUTONOMIC DYSREFLEXIA; CONSTIPATION; CONTROLLED STUDY; CYSTALGIA; CYSTOMETRY; DETRUSOR MUSCLE; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; HEADACHE; HEMATURIA; HUMAN; HYPERTENSION; INJECTION SITE; INTERMITTENT CATHETERIZATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; NAUSEA; OVERACTIVE BLADDER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SPINAL CORD INJURY; TREATMENT DURATION; URINARY TRACT INFECTION; URINE INCONTINENCE; URINE RETENTION; VAGINA MYCOSIS; VULVOVAGINAL DISEASE;

ADULT; BOTULINUM TOXINS, TYPE A; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROMUSCULAR AGENTS; QUALITY OF LIFE; SPINAL CORD INJURIES; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE;

EID: 84861095162     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2012.01.125     Document Type: Article

References (19)

1. C.J. Fowler, D. Griffiths, W.C. de Groat The neural control of micturition Nat Rev Neurosci 9 2008 453
2. M.B. Chancellor, R.U. Anderson, T.B. Boone Pharmacotherapy for neurogenic detrusor overactivity Am J Phys Med Rehabil 85 2006 536
3. M. Stohrer, B. Blok, D. Castro-Diaz EAU guidelines on neurogenic lower urinary tract dysfunction Eur Urol 56 2009 81
4. S.J. Foley, J.P. McFarlane, P.J. Shah Vesico-ureteric reflux in adult patients with spinal injury Br J Urol 79 1997 888
5. W. Hollingworth, J.D. Campbell, J. Kowalski Exploring the impact of changes in neurogenic urinary incontinence frequency and condition-specific quality of life on preference-based outcomes Qual Life Res 19 2010 323
6. B. Schurch, P. Denys, C.M. Kozma Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence Eur Urol 52 2007 850
7. B. Schurch, P. Denys, C.M. Kozma Reliability and validity of the Incontinence Quality of Life questionnaire in patients with neurogenic urinary incontinence Arch Phys Med Rehabil 88 2007 646
8. K. Jundt, K. Schreyer, K. Friese Anticholinergic therapy: do the patients take the pills prescribed? Arch Gynecol Obstet 284 2011 663
9. R. DasGupta, C.J. Fowler Bladder, bowel and sexual dysfunction in multiple sclerosis: management strategies Drugs 63 2003 153
10. B.T. Benevento, M.L. Sipski Neurogenic bladder, neurogenic bowel, and sexual dysfunction in people with spinal cord injury Phys Ther 82 2002 601
11. B. Schurch, M. Stohrer, G. Kramer Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results J Urol 164 2000 692
12. B. Schurch, M. de Seze, P. Denys Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study J Urol 174 2005 196
13. D.L. Patrick, M.L. Martin, D.M. Bushnell Quality of life of women with urinary incontinence: further development of the incontinence quality of life instrument (I-QOL) Urology 53 1999 71
14. C.L. Hatheway, C. Dang Immunogenicity of the neurotoxins of Clostridium botulinum J. Jankovic, M. Hallett, Therapy with Botulinum Toxin 1994 Marcel Dekker New York 93 107
15. G. Karsenty, P. Denys, G. Amarenco Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/ neurogenic overactive bladder: a systematic literature review Eur Urol 53 2008 275
16. F. Cruz, S. Herschorn, J. Heesakkers Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomized, double-blind, placebo-controlled trial Eur Urol 60 2011 742
17. K.P. Johnson, B.R. Brooks, J.A. Cohen Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial Copolymer 1 Multiple Sclerosis Study Group Neurology 45 1995 1268
18. M.S. Freedman Long-term follow-up of clinical trials of multiple sclerosis therapies Neurology 76 2011 S26
19. A. Manack, S.P. Motsko, C. Haag-Molkenteller Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database Neurourol Urodyn 30 2011 395